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The human papillomavirus (HPV) type 16 (HPV16) E6 protein stimulates transcription of the catalytic
subunit of telomerase, hTERT, in epithelial cells. It has been reported that binding to the ubiquitin ligase E6AP
is required for this E6 activity, with E6 directing E6AP to the hTERT promoter. We previously reported two
E6AP binding-defective HPV16 E6 mutations that induced immortalization of human mammary epithelial
cells. Because activation of hTERT is proposed to be necessary for epithelial cell immortalization, we sought
to further characterize the relationship between E6/E6AP association and telomerase induction. We demon-
strate that while these E6 mutants do not bind E6AP, they retain the capability to stimulate the expression of
hTERT. Chromatin immunoprecipitation assays confirmed the presence of Myc, wild-type E6, and the E6AP
binding-defective E6 mutants, but not E6AP itself, at the endogenous hTERT promoter. Interestingly, an
immortalization-defective E6 mutant localized to the hTERT promoter but failed to increase transcription. We
conclude that binding to E6AP is not necessary for E6 localization to or activation of the hTERT promoter and
that another activity of E6 is involved in hTERT activation.
The best-characterized property of the E6 protein of the
cancer-associated human papillomavirus (HPV) is the degra-
dation of p53 mediated by the ubiquitin ligase E6AP (20, 38).
Additionally, E6 has several p53-independent activities. HPV
type 16 (HPV16) E6 binds to and inhibits the transactivation
functions of histone acetyltransferase (HAT) proteins CBP
and p300 (36, 51). E6 also interacts with the calcium binding
protein E6BP/ERC-55, the Rap GTPase-activating protein
E6TP1, and the p53 coactivator hAda3 (8, 15, 27). An impor-
tant activity of E6 thought to be necessary for epithelial cell
immortalization is its ability to increase telomerase activity (16,
26, 35).
Telomerase is a ribonucleoprotein complex that maintains
telomere length. Its RNA subunit serves as a template for the
synthesis of telomeric DNA, and its catalytic subunit has been
shown to be necessary for telomerase enzymatic activity (49).
Most somatic cells have no or very low telomerase activity (4).
Senescence can be bypassed, and several primary human cell
types can be immortalized, by forced expression of the telo-
merase catalytic subunit hTERT (4, 24, 44). Cellular onco-
genes, as well as HPV16 E6, are known to induce hTERT
transcription (10, 26, 28, 47). The hTERT core promoter re-
gion contains E and GC boxes with recognition sites for tran-
scription factors including Myc, SP-1, and USF (9, 17, 18, 42).
Myc activates hTERT, while other factors, such as Mad, Sip1,
and Menin, repress hTERT expression (19, 28, 34). Myc and
Mad are highly unstable proteins and function by forming
dimers with the stable protein Max (3, 12). It has been sug-
gested that the hTERT promoter is differentially regulated by
switching binding between Myc/Max and Mad/Max dimers
(48). This is supported by the finding that Myc/Max complexes
were dominant in immortal cells with high telomerase activity
while Mad/Max dimers were abundant in mortal cells (34).
In contrast to Myc, which induces telomerase in both epi-
thelial cells and fibroblasts, HPV16 E6 activation of telomerase
is limited to epithelial cells (26). How E6 activates telomerase
has not been resolved. E6 mutants unable to induce p53 deg-
radation still increased hTERT expression, implying that telo-
merase activation by E6 is a p53-independent effect (26, 31).
Subsequent reports have proposed several mechanisms for E6
activation of hTERT. In one model, Myc binds to E6 and
translocates the E6/E6AP complex to the hTERT regulatory
elements, as evidenced by chromatin immunoprecipitation
(ChIP) data showing E6 and E6AP localized to the minimal
hTERT promoter (45). In another model, the E6/E6AP com-
plex stimulates the degradation of NFX-1, a constitutive re-
pressor of hTERT transcription (17). A third group suggested
that the USF transcription factor regulates hTERT transcrip-
tion. These authors reported that Myc replaces USF at the
hTERT promoter in cells expressing E6 (32). It has also been
suggested that p300- and E6AP-dependent histone acetylation
is involved in E6-induced telomerase activation (21).
While it has been reported that the activation of hTERT in
human keratinocytes requires the binding of E6 to E6AP, only
a few E6 mutations have been characterized (16, 30, 45). We
had previously identified HPV16 E6 mutants that were defec-
tive in binding to E6AP yet produced immortal mammary
epithelial cells (MECs), so we suspected that these mutants
retained the ability to increase telomerase levels (31). We
therefore sought to further characterize the relationship be-
tween E6AP association and telomerase activation by using an
expanded series of E6 mutations.
MATERIALS AND METHODS
Retrovirus infection. Transfection of LinX-A packaging cells and retrovirus
production were performed as described elsewhere (41).
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Cell culture. Primary human foreskin keratinocytes were maintained in kera-
tinocyte serum-free medium (KSFM; Invitrogen) or on feeder layers in F me-
dium (14). Keratinocytes were infected with LXSN retroviruses expressing
HPV16 E6 or one of its mutants and were selected with G418 (100 g/ml) for 10
days. H1299 cells were maintained in RPMI–10% serum medium (Invitrogen).
Plasmids. Flag-pcDNA3-16 E6 and its L37S mutant were kind gifts from
Cheng-Ming Chiang (UT-Southwestern). Flag-pcDNA3-L110Q was generated
by site-directed mutagenesis (QuikChange; Stratagene).
Real-time reverse transcription-PCR (RT-PCR). Total RNA was isolated with
an RNeasy kit (Qiagen). One microgram of total RNA was used for synthesis of
first-strand cDNA with random primers and the Superscript III system (Invitro-
gen). Ten percent of the first-strand synthesis reaction product was used for
TaqMan PCR on an MJ Research PCR cycler. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was amplified using a SYBR green mix (S-7563;
Molecular Probes) and was used as a loading control. The following primer pairs
were used: GAPDH-G3S (ACCACAGTCCATGCCATCAC) and -G3A (TCC
ACCACCCTGTTGCTGTA) and hTERT forward (TTCTTGTTGGTGACAC
CTCACCTC) and reverse (ACAGGGAAGTTCACCACTGTCTTC) primers.
The TaqMan hTERT probe (TGAGTATGGCTGCGTGGTGAACTT) was
combined with the hTERT forward and reverse primers. E6 gene expression was
quantified using a SYBR green mix with E6 forward (AAGCAACAGTTACTG
CGACGTGAG) and reverse (CGGTCCACCGACCCTTATATT) primers.
hTERT and E6 levels were normalized to GAPDH levels.
In vitro binding assay. One microgram of glutathione S-transferase (GST)-
E6AP protein was incubated with in vitro-translated 35S-labeled E6 proteins and
protein A-Sepharose beads in low-salt association buffer (100 mM NaCl, 100 mM
Tris-Cl [pH 8.0], 0.1% NP-40) for 1 h at 4°C (31). The beads were washed four
times in the same buffer and loaded onto a 15% sodium dodecyl sulfate-acryl-
amide gel.
Quantitative binding assay. In brief, E6AP and the human homologue of the
Drosophila discs large tumor suppressor protein (hDLG) were fused in frame to
the N terminus of bacterial alkaline phosphatase (BAP) and purified from
Escherichia coli (2). E6 mutants were expressed as GST fusion proteins. Equiv-
alent amounts of GST fusion proteins were immobilized on glutathione beads
and plated into 96-well filter plates (500 ng/well). Saturation was determined by
binding increasing amounts of E6AP-BAP or hDLG-BAP in 50 l at room
temperature for 1 h. Bound E6AP-BAP or hDLG-BAP was measured in
relative light units using an Immunostar-AP substrate (Bio-Rad). Nonlinear
regression was used to calculate disassociation constants (Kd) with Prism
software.
ChIP assay. Human foreskin keratinocytes infected with recombinant retro-
viruses expressing HPV16 E6 mutants were used for a ChIP assay, which was
performed as described previously (50). Primers used to amplify endogenous
hTERT have been described previously (45).
Coimmunoprecipitation experiments. A total of 106 H1299 cells were trans-
fected with 2 g of Flag-pcDNA3 expressing HPV16 E6 or the L37S or L110Q
mutant along with 2 g of Flag-pcDNA3-E6AP. Cells were treated with the
proteasome inhibitor MG132 and were harvested 24 h after transfection; cell
pellets were frozen at 80°C, thawed on ice, and lysed with 50 mM Tris-Cl (pH
8.0), 1% NP-40, 150 mM NaCl, and 2 mM EDTA. E6AP-bound complexes were
collected using an anti-E6AP antibody and were probed after immunoblotting
with anti-Flag or anti-E6AP antibodies.
Antibodies. The following antibodies were used in the ChIP assay: anti-HPV16
E6 (1), anti-Myc (9E10; Santa Cruz Biotechnology), anti-E6AP (N-14; Santa
Cruz Biotechnology), and anti-actin (C-2; Santa Cruz Biotechnology). For im-
munoprecipitations and immunoblotting, we used anti-Flag antibody M2 (Sigma)
and anti-E6AP antibody N-14 (Santa Cruz Biotechnology).
RESULTS AND DISCUSSION
We have previously reported the characterization of mutants
of HPV16 E6 that could neither bind E6AP nor induce the
degradation of p53 yet retained the ability to immortalize
MECs (31). These observations superficially appeared to chal-
lenge the prevailing notion that both p53 pathway inactivation
and reactivation of telomerase are necessary for the inhibition
of replicative senescence in epithelial cells. Our subsequent
investigations revealed that hAda3 is a critical effector of se-
nescence signaling to p53 that involves its acetylation and sta-
bilization and that E6 mutants capable of inducing hAda3
degradation block p53-dependent senescence (39; V. A. Sha-
manin, P. Sekaric, and E. J. Androphy, submitted for publica-
tion). In this study, we sought to understand whether and how
these E6 mutants activate hTERT.
We selected five HPV16 E6 mutants for these investigations.
The L37S and L110Q mutants were previously identified as
defective in association with E6AP but competent at MEC
immortalization (31). The L50G mutant has been reported not
to bind E6AP (51) and did not immortalize MECs (Shamanin
et al., submitted), and the G130V mutant had a phenotype
identical to that of the L50G mutant in both these assays
(Shamanin et al., submitted). The F2V mutant was included
for comparison, since we previously reported that it bound
E6AP and immortalized MECs (31). To correlate E6 binding
to E6AP with hTERT induction, we initially evaluated the
direct interaction of HPV16 E6 and the five mutants with
E6AP by using a standard GST pulldown assay. As expected,
wild-type HPV16 E6 and the F2V mutant efficiently bound to
GST-E6AP, while the G130V, L50G, L37S, and L110Q mu-
tants displayed no distinguishable binding above background
(Fig. 1). However, this assay measures binding by using a fixed
amount of GST-E6AP and undefined concentrations of wild-
type and mutant E6 proteins. Therefore, we utilized a quanti-
tative binding assay in which a fixed concentration of each
GST-E6 protein was incubated with increasing concentrations
of E6AP-BAP fusion protein (2; J. J. Cherry and E. J. Andro-
phy, unpublished data). Only wild-type E6 and F2V E6 dis-
played E6AP-BAP binding that was significantly (P  0.001 by
two-way analysis of variance) greater than that for the GST
control (Fig. 2); the Kd determined for wild-type HPV16 E6
and F2V E6 were 38  15 nM and 57  9 nM, respectively.
The L50G, G130V, L37S, and L110Q E6 mutants were defec-
tive for binding even at the highest concentrations of the
E6AP-BAP ligand (Fig. 2), so Kd could not be calculated. To
verify that the GST-E6 fusion proteins were active, equal
amounts were tested for binding to a BAP fusion containing
the three PDZ domains of the hDLG protein (25). This do-
main remains intact in all the mutant GST-E6 fusion proteins
studied here. As with the E6AP-BAP binding reactions, a
constant amount of each GST-E6 fusion protein was incubated
with increasing concentrations of the hDLG-BAP fusion pro-
tein (Fig. 2). All GST-E6 proteins bound to hDLG-BAP with
FIG. 1. Mutational analysis of E6 binding to E6AP. GST-E6AP
was incubated with in vitro-translated wild-type HPV16 E6 (16E6) and
the G130V and L50G (top panel) and F2V, L37S, and L110Q (bottom
panel) mutants. Background is shown in the last lane of each panel, in
which GST alone (GST C) was used as a negative control.
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similar efficiencies, at an average Kd of 6 nM and with no
significant differences in the saturation binding curves (P 
0.05 by a two-way analysis of variance).
A recent report demonstrated association between E6 and
E6AP by immunoprecipitation (5). To confirm our in vitro
binding data, we used transient transfection of E6 and E6AP
into H1299 cells, which do not express p53, so any interaction
would be p53 independent. Because it has been reported that
E6 binding induces autoubiquitination and destruction of
E6AP, cells were treated with the proteasome inhibitor
MG132 (5, 22). Immunoprecipitations with an anti-E6AP an-
tibody showed that the complexes captured wild-type HPV16
E6 but not the L37S and L110Q mutants (Fig. 3), confirming
the inability of these mutants to bind E6AP.
We then addressed the question of whether these E6AP
binding-defective, MEC immortalization-competent E6 mu-
tants could increase the expression of hTERT. For these ex-
periments, we preferred to examine endogenous hTERT tran-
scription rather than transfecting an hTERT promoter-based
reporter construct, and human keratinocytes (HKs) were cho-
sen, because they are the natural target cells of HPV. Recom-
binant retroviruses expressing wild-type E6 and E6 mutants
were used to infect early-passage HKs, since these cells are
inefficiently transfected using DNA. Wild-type and F2V mu-
tant E6 proteins, which both bind E6AP, increased endoge-
nous hTERT transcription in the infected HKs. The E6AP
binding-defective G130V and L50G E6 mutants did not stim-
ulate hTERT expression (Fig. 4A). However, the L37S and
L110Q E6 mutants, which are equally defective for E6AP
binding, activated endogenous hTERT expression to levels
similar to those for wild-type E6 and the F2V mutant. Since
hTERT induction might be dependent on E6 levels, we quan-
tified E6 expression by real-time PCR in keratinocytes infected
with these E6 mutants and showed that they have similar
expression of E6 mRNA (Fig. 4B). Taken together, these re-
sults demonstrate that E6 binding to E6AP is not required for
hTERT induction.
Another aspect of the proposed model is that HPV16 E6 is
present at the hTERT promoter (45). We performed ChIP
experiments to test for wild-type and mutant HPV16 E6 pro-
teins on the endogenous hTERT promoter in keratinocytes
following retrovirus infections. An anti-E6 peptide serum, but
not preimmune serum, immunoprecipitated the hTERT pro-
moter DNA, as predicted (Fig. 5A). We then queried whether
the E6AP binding-defective E6 mutants could still localize to
the hTERT promoter. We selected for comparison two E6AP
binding-defective E6 mutants: the L110Q mutant, which in-
duced hTERT, and the L50G mutant, which did not. Notably,
both the L110Q and L50G E6 proteins associated with the
endogenous hTERT promoter by ChIP assay (Fig. 5A), imply-
ing that E6AP binding is not necessary to target E6 to the
hTERT promoter. Interestingly, the L50G data suggest that E6
localization at the hTERT promoter is not sufficient for
hTERT induction, while the L37S and L110Q results suggest
the involvement of an activity distinct from E6AP binding.
E6AP has been detected at the hTERT promoter in the
presence of E6, suggesting that the E6/E6AP complex might
target a telomerase repressor for ubiquitin-mediated proteol-
ysis (30). We performed ChIP assays using a commercially
available anti-E6AP antibody (N-14; Santa Cruz) and an anti-
FIG. 2. Quantitative binding assay. Five hundred nanograms of
each GST-E6 fusion protein was incubated with increasing concentra-
tions of portions of E6AP or hDLG fused to BAP (ligand) in a final
volume of 50 l. After a wash, bound ligand was determined as relative
light units (RLU). (A) Binding of GST-E6 proteins to increasing
concentrations (0 to 400 nM) of E6AP-BAP. E6 and the F2V mutant
bound E6AP and reached saturation; the L37S, L50G, L110Q, and
G130V mutants did not bind to the ligand. (B) Binding of GST-E6
proteins to increasing concentrations (0 to 200 nM) of hDLG-BAP. All
E6 proteins bound this ligand and reached saturation.
FIG. 3. The HPV16 E6 L37S and L110Q mutants do not associate
with E6AP in vivo. H1299 cells were transfected with Flag-pcDNA3-16
E6, -L37S, or -L110Q and Flag-pcDNA3-E6AP. Cells were treated with
MG132 and harvested 24 h after transfection. To demonstrate the asso-
ciation between E6 and E6AP, cell lysates were immunoprecipitated with
an anti-E6AP antibody, and bound complexes were immunoblotted
with an anti-E6AP or anti-Flag antibody. E6AP immunoprecipitated
only with wild-type E6, not with E6 L37S or L110Q.
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E6AP peptide antiserum, both confirmed to recognize cotrans-
fected epitope tagged E6AP by immunoprecipitation (data not
shown). These ChIP experiments were unable to detect E6AP
on the endogenous hTERT promoter in HKs in the presence
or absence of wild-type E6 (data not shown).
Binding of Myc to specific E boxes within the hTERT en-
hancer elements activates hTERT transcription (9, 19). Myc
and its associated E box sites are also critical for E6 induction
of hTERT transcription, and experimental evidence indicates
that Myc binds and transfers E6 to these regulatory sites (16,
32, 35, 45). We therefore tested for the presence of Myc at the
hTERT promoter and asked whether this correlates with E6-
mediated activation. We performed ChIP assays using extracts
from HKs infected with a retrovirus expressing either wild-type
E6 or the L110Q (hTERT-activating) or L50G (defective for
hTERT induction) E6AP binding-defective mutant. Binding of
Myc to the hTERT promoter was detected in HKs in the
absence of E6 as well as in cells expressing wild-type or mutant
E6 (Fig. 5B), while no hTERT PCR products were visualized
by using a control anti-actin antibody. These results reproduce
prior data (30, 45) showing that Myc bound to the hTERT
promoter in the absence of E6. In contrast, a recent study
detected Myc at the hTERT promoter only in cells expressing
E6 and found that E6 increased Myc protein levels (32). In our
experiments, E6 did not alter the levels of total Myc protein in
the HKs (data not shown), in agreement with other reports (16,
35, 45).
The discrepancies in Myc protein levels may be explained by
differences in cell culture methods. In our experiments, HKs
were maintained on feeder layers before retrovirus infection,
with subsequent transfer to KSFM. It has been shown that
keratinocyte growth conditions (feeder layers versus a minimal
medium such as KSFM) can modulate telomerase expression
(14). Additionally, Myc is known to interact with HAT com-
plexes SAGA and GCN5 (13, 29), and GCN5, TIP60, CBP,
and p300 have been shown to mediate Myc acetylation (11, 37,
46). Ablation of p300 also increased histone acetylation and
caused hTERT activation, implying that p300 acts as a repres-
sor of telomerase (21). E6 has been reported to interact with
HAT complex proteins such as p300 and hAda3 (27, 36) and to
inhibit p53 acetylation (39, 43). It is therefore possible that
acetylation of Myc, rather than its phosphorylation or alter-
ations in the total levels of Myc or its binding partners Mad
and Max, is involved in hTERT activation (45). Future studies
should reveal whether E6 alters Myc acetylation and whether
this regulates hTERT activation.
Our data appear to conflict with the concept that E6 must
bind to E6AP in order to activate hTERT (16, 30). Using
reporter and telomere repeat amplification protocol assays,
previous studies showed that the HPV16 8S9A10T E6 mutant,
which binds E6AP, could activate telomerase while the E6AP
FIG. 4. E6AP binding is not required for hTERT activation. Primary HKs were infected with HPV16 E6-expressing retroviruses. Real-time
RT-PCR was performed on extracted RNA using TaqMan oligonucleotides specific for hTERT and SYBR green for E6 in parallel with GAPDH
for normalization. (A) Ratio of hTERT to GAPDH amplification. The L37S and L110Q E6AP binding-defective mutants activated hTERT to
levels similar to those for wild-type HPV16 E6 and the F2V mutant. The L50G and G130V mutants did not increase hTERT transcript levels more
than the control (C) retrovirus. (B) Ratio of E6 expression to GAPDH expression.
FIG. 5. ChIP assays for E6 and Myc at the hTERT promoter. HKs
were infected with HPV16 E6-expressing retroviruses and treated with
formaldehyde. Extracts were immunoprecipitated, the cross-linking
reversed, and PCR performed with primers to amplify hTERT DNA.
The input is the extract prior to immunoprecipitation that was subject
to PCR. (A) ChIP assay with antiserum to E6 or preimmune serum
(PI). E6AP binding-defective HPV16 E6 mutants associate with the
endogenous hTERT promoter. E6 mutants were detected at the
hTERT promoter by using an anti-E6 peptide antibody. No E6 signal
was detected in cells expressing retroviral backbone DNA (lanes C).
(B) A ChIP assay using an anti-Myc antibody detects Myc at the
hTERT promoter in HKs infected with control (lanes C) and E6-
expressing retroviruses. An anti-actin antibody was used as a control.
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binding-defective 9-13 mutant, with a 5-amino-acid deletion,
was inactive. Another study suggested that E6AP binding is
important for telomerase activation, since E6AP binding-de-
fective deletion mutants (123-127, 118-122, and 146-151)
of E6 did not induce telomerase in a telomere repeat ampli-
fication protocol assay (24, 26). We investigated the activation
of endogenous hTERT by real-time RT-PCR. By analyzing E6
mutants with single amino acid substitutions, we find that E6/
E6AP interaction is not required for the activation of the
endogenous hTERT promoter. Interestingly, the leucine at
position 110, which was able to stimulate hTERT and induce
MEC immortalization (31), has been reported to be buried at
a hydrophobic interface of the proposed E6 structural model
(33). Substitution of charged glutamine is likely to disrupt this
fold. However, the reported structure was modeled from nu-
clear magnetic resonance data for a C-terminal portion of E6
and may not accurately reproduce the native conformation of
the E6 protein.
The E6/E6AP complex was reported to bind two isoforms of
NFX1: NFX1-91 and NFX1-123 (17). NFX1 was demonstrated
to repress hTERT transcription, and E6 interfered with this
repression by destabilizing NFX1-91, presumably through
E6AP-mediated ubiquitination. Our data demonstrate that
E6AP is not required for hTERT activation and therefore
suggest that NFX1-91 destabilization is not necessary or that
another E6-dependent pathway may specifically target NFX1-
91. This is consistent with recent observations that E6-induced
p53 degradation in vivo may occur through E6AP-dependent
and E6AP-independent mechanisms (6, 7, 40).
The NFX1-123 protein was a strong activator of hTERT in
human keratinocytes expressing HPV16 E6 (23). E6 bound
NFX1-123 in the absence of E6AP and did not induce its
degradation. These authors suggested that E6 recruits NFX1-
123 to the hTERT promoter. Since we show that the E6AP
binding-defective L110Q and L37S E6 mutants activate
hTERT, one possible scenario is that these mutants retain the
ability to interact with NFX-123 and to target it to the hTERT
promoter. The L50G mutant does not bind E6AP but was
found localized to the hTERT promoter; still, it did not induce
hTERT transcription. It is possible that the L50G mutant lacks
the ability to interact with NFX-123.
Our data reveal a direct correlation between telomerase
activation and immortalization, since mutants that induce
hTERT (the F2V, L37S, and L110Q mutants [Fig. 4A]) im-
mortalize MECs (31). The 9-13, 123-127, and 146-151 E6
deletion mutants were defective for telomerase activation and
failed to immortalize MECs (24). Taken together, our results
strongly suggest that induction of hTERT is necessary for
MEC immortalization. We have not yet studied the E6 activ-
ities necessary for human keratinocyte immortalization due to
the confounding requirement for E7. The characterization of
these HPV16 E6 mutants should facilitate such studies.
In conclusion, we demonstrate that E6 binding to the ubiq-
uitin ligase E6AP is not necessary for E6 localization to the
hTERT promoter or for induction of hTERT transcription.
Moreover, recruitment of E6 to the hTERT promoter is not
sufficient for telomerase activation, since the E6 L50G mutant
was present at the hTERT promoter but did not activate
hTERT. Further studies are required to determine the precise
mechanism by which E6 stimulates hTERT transcription.
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